经济观察网 基于已知信息，维力医疗（603309）（股票代码：603309）在2026年有以下值得关注的事 件，主要涉及产能扩张、公司治理及政策利好等方面。以下内容基于公开资料整理，事件按时间顺序或 重要性列出。 公司项目推进 子公司发展 全资子公司狼和医疗于2025年获得高新技术企业重新认定，预计可享受税收优惠；此外，子公司海南维 力医疗的一次性使用亲水涂层可视鼻胃肠管入选海南省创新药械产品目录（第四批），将享受地方政策 支持，有助于提升市场竞争力。 公司状况 控股股东股权质押改善：控股股东高博投资于2025年12月30日提前解除2000万股质押，截至2025年12月 31日质押率降至28.25%，这一举措可能增强公司治理稳定性。 业绩预告披露：公司于2026年1月7日发布2025年全年业绩预告，预计净利润同比下滑57%-66%，主要因 子公司经营业绩下滑及商誉减值影响，后续需关注正式审计报告发布。 维力医疗的印尼工厂计划于2026年3月开启小批量试生产，并于4月正式投入生产。该工厂一期主要生产 护理类产品（如吸引连接管），设计年产能为4000万支，所有产品均供应美国大客户；二期规划涉及麻 醉类产品（如气管 ...

Core Viewpoint - Vili Medical (603309) is experiencing a significant decline in expected net profit for 2025, primarily due to the poor performance of its wholly-owned subsidiary, Jiangxi Langhe Medical Equipment Co., Ltd. [1][2] Performance Disclosure Highlights - Vili Medical anticipates a net profit attributable to shareholders of 75 million to 95 million yuan for 2025, representing a year-on-year decrease of 66% to 57% [1][2][4] - The net profit after deducting non-recurring items is expected to be between 65 million and 85 million yuan, reflecting a year-on-year decline of 69% to 60% [1][2][4] - The decline in performance is mainly attributed to the operational downturn of Jiangxi Langhe Medical Equipment Co., Ltd., and the company plans to recognize goodwill impairment of 147 million yuan, subject to final audit and assessment results [1][2] Company Announcements Summary - Vili Medical's wholly-owned subsidiary, Hainan Vili Medical Technology Development Co., Ltd., has had its hydrophilic coated visible nasogastric tube included in the fourth batch of innovative drug and medical device product catalog in Hainan Province, which will enhance brand recognition and market competitiveness, although the short-term impact on financial performance is expected to be minimal [2][4] - The company plans to utilize up to 350 million yuan of idle self-owned funds for cash management, investing in low-risk, liquid, and safe financial products with a maximum investment period of 12 months [2][4] - For the year 2026, Vili Medical expects to engage in related party transactions totaling no more than 75 million yuan, with procurement from Guangzhou Shimei Packaging Industry Co., Ltd. not exceeding 15 million yuan and sales to Unoquip GmbH not exceeding 60 million yuan [3][4]

Group 1 - The core announcement is that Guangzhou Welly Medical Instrument Co., Ltd.'s wholly-owned subsidiary, Hainan Welly Medical Technology Development Co., Ltd., has had its product, a disposable hydrophilic coated visible nasogastric tube, included in the Hainan Province Innovation Medical Device Product Directory (Fourth Batch) [2][3] Group 2 - The inclusion of the innovative product in the directory is a recognition of the product's technological advancement and innovation, which is expected to enhance the company's brand awareness and market competitiveness [3] - The selected product will benefit from a series of supportive policies aimed at promoting the development of innovative medical devices in Hainan Province, positively impacting future sales [3] - The company plans to leverage this inclusion as an opportunity to increase its research and development efforts in innovative medical devices, enhance its independent innovation capabilities, and contribute to the high-quality development of the regional biopharmaceutical industry [3]

Group 1 - The core point of the article is that Weili Medical's wholly-owned subsidiary, Hainan Weili Medical Technology Development Co., Ltd., has had its hydrophilic coated visible nasogastric tube included in the fourth batch of innovative drug and medical device product catalog in Hainan Province, which will benefit sales through local innovation support policies [2] Group 2 - The inclusion of the product in the catalog is expected to provide long-term benefits for the company's sales [2]

Core Viewpoint - Weili Medical's subsidiary, Hainan Weili, has been recognized for its innovative product, the hydrophilic coated visible nasogastric tube, which has been included in the fourth batch of the Hainan Province innovative medical device product catalog [1] Group 1: Product Recognition - The inclusion of the hydrophilic coated visible nasogastric tube in the Hainan Province innovative medical device product catalog signifies recognition of the product's technological advancement and innovation [1] - This recognition is expected to enhance the company's brand awareness and market competitiveness [1] Group 2: Support Policies - The selected product will benefit from a series of supportive policies aimed at promoting the development of innovative medical devices in Hainan Province, which is anticipated to positively impact future sales [1] Group 3: R&D Commitment - The company plans to leverage this recognition to further increase its research and development efforts in innovative medical devices, aiming to strengthen its independent innovation capabilities [1] - The company is committed to aligning with local industrial development strategies to contribute to the high-quality development of the regional biopharmaceutical industry [1]

Core Viewpoint - The company, Weili Medical, has received recognition for its innovative product, the hydrophilic coated visual nasogastric tube, which has been included in the fourth batch of the Hainan Province innovative medical device product catalog, enhancing its brand visibility and market competitiveness [1] Group 1 - Weili Medical's wholly-owned subsidiary, Hainan Weili Medical Technology Development Co., Ltd., has been notified of its product's inclusion in the Hainan Province innovative medical device product catalog [1] - The inclusion of the innovative product is a recognition of the company's technological advancement and innovation [1] - The selected product will benefit from a series of supportive policies aimed at promoting the development of innovative medical devices in Hainan Province, positively impacting future sales [1] Group 2 - The company plans to leverage this inclusion as an opportunity to increase its research and development efforts in innovative medical devices [1] - The company aims to enhance its independent innovation capabilities and actively respond to local industrial development strategies [1] - The company is committed to contributing to the high-quality development of the regional biopharmaceutical industry [1]

Core Viewpoint - The company, Weili Medical, has announced that its wholly-owned subsidiary, Hainan Weili Medical Technology Development Co., Ltd., has received notification regarding the inclusion of its product, the single-use hydrophilic coated visible nasogastric tube, in the fourth batch of the Hainan Province innovative medical device product catalog [1] Group 1 - Weili Medical's product has been officially recognized and included in the Hainan Province innovative medical device product catalog [1] - The product is identified as a single-use hydrophilic coated visible nasogastric tube with the registration number Qiong Medical Approval 20252140055 [1] - This inclusion may enhance the company's market presence and potential sales in the region [1]

Core Points - Vili Medical (603309) closed at 12.93 yuan on July 11, 2025, up 0.7% from the previous week [1] - The company's total market capitalization is 3.787 billion yuan, ranking 90th out of 126 in the medical device sector and 3795th out of 5149 in the A-share market [1] Company Announcements - Vili Medical's wholly-owned subsidiary, Hainan Vili, received a Class II medical device registration certificate for a single-use hydrophilic coated visual nasogastric tube [1] - The product is designed for delivering nutrients, gastric decompression, and flushing, consisting of a feeding connector, gastric tube, and a bullet head with a camera [1] - The registration certificate was issued on July 7, 2025, and is valid until July 6, 2030 [1] - Currently, there are no similar products available in the domestic market, which may enhance the subsidiary's product variety and market competitiveness [1] - Although the registration is expected to positively impact the company's operations, the product has not yet been marketed, and its short-term effect on financial performance is minimal [1] - The actual sales performance will depend on future marketing efforts, and the specific impact on the company's future financial results remains uncertain [1]